S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The #1 Crypto for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
He Is Giving Away Bitcoin (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The #1 Crypto for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
He Is Giving Away Bitcoin (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The #1 Crypto for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
He Is Giving Away Bitcoin (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The #1 Crypto for 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
He Is Giving Away Bitcoin (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free TALS Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$15.61
▼
$16.66
50-Day Range
$12.36
▼
$28.36
52-Week Range
$0.89
▼
$27.95
Volume
547,175 shs
Average Volume
386,531 shs
Market Capitalization
$669.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSocial Media
TALS stock logo

About Talaris Therapeutics Stock (NASDAQ:TALS)

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

TALS Stock News Headlines

February 25, 2024 | benzinga.com
Longitude Venture Partners III, L.P.'s Net Worth
November 1, 2023 | msn.com
Talaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15
April 18, 2024 | TradeSmith (Ad)
A.I. Pioneer Issues Urgent Warning to Americans
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
October 19, 2023 | msn.com
Talaris Therapeutics goes ex-dividend tomorrow
October 18, 2023 | finanznachrichten.de
Talaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
October 17, 2023 | msn.com
Talaris shareholders approve merger, 1-for-10 reverse stock split
October 17, 2023 | finance.yahoo.com
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
October 6, 2023 | marketwatch.com
Shares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Merger
April 18, 2024 | TradeSmith (Ad)
A.I. Pioneer Issues Urgent Warning to Americans
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
October 6, 2023 | finance.yahoo.com
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
October 4, 2023 | finance.yahoo.com
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
September 12, 2023 | finance.yahoo.com
We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
August 15, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOT
August 14, 2023 | finance.yahoo.com
ImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Business
August 8, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF
July 28, 2023 | benzinga.com
Moore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firm
July 27, 2023 | markets.businessinsider.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)
July 18, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMS
July 18, 2023 | msn.com
Talaris Therapeutics: Cashing Out Ahead Of Tourmaline Merger
July 6, 2023 | msn.com
Talaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75
June 27, 2023 | markets.businessinsider.com
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI
June 26, 2023 | businesswire.com
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
June 23, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. Merger
June 23, 2023 | bizjournals.com
Talaris Therapeutics announces merger after layoffs
June 22, 2023 | bizjournals.com
NY biotech to go public by merging with Boston firm that laid off 95% of staff
June 22, 2023 | msn.com
Talaris jumps 29% on merger with Tourmaline Bio in all-stock deal
June 22, 2023 | markets.businessinsider.com
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
See More Headlines
Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TALS
CUSIP
N/A
CIK
1827506
Web
talaristx.com
Phone
502-398-9250
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-73,890,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.93%
Return on Assets
-37.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.41
Quick Ratio
15.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.33 per share
Price / Book
3.85

Miscellaneous

Outstanding Shares
42,764,000
Free Float
35,708,000
Market Cap
$713.30 million
Optionable
Not Optionable
Beta
2.18
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

TALS Stock Analysis - Frequently Asked Questions

How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03.

How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics?

Talaris Therapeutics announced a dividend on Thursday, October 19th. Shareholders of record on Monday, October 16th will be paid a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date is Friday, October 20th.
Read our dividend analysis for TALS.

When did Talaris Therapeutics IPO?

Talaris Therapeutics (TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO.

This page (NASDAQ:TALS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
SHOCKING Crypto Leak…
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
How Biden has already won 2024
Porter & Company